184 related articles for article (PubMed ID: 26500282)
21. Loss of PIM2 enhances the anti-proliferative effect of the pan-PIM kinase inhibitor AZD1208 in non-Hodgkin lymphomas.
Kreuz S; Holmes KB; Tooze RM; Lefevre PF
Mol Cancer; 2015 Dec; 14():205. PubMed ID: 26643319
[TBL] [Abstract][Full Text] [Related]
22. mTORC1 upregulation via ERK-dependent gene expression change confers intrinsic resistance to MEK inhibitors in oncogenic KRas-mutant cancer cells.
Komatsu N; Fujita Y; Matsuda M; Aoki K
Oncogene; 2015 Nov; 34(45):5607-16. PubMed ID: 25703330
[TBL] [Abstract][Full Text] [Related]
23. A plastic SQSTM1/p62-dependent autophagic reserve maintains proteostasis and determines proteasome inhibitor susceptibility in multiple myeloma cells.
Milan E; Perini T; Resnati M; Orfanelli U; Oliva L; Raimondi A; Cascio P; Bachi A; Marcatti M; Ciceri F; Cenci S
Autophagy; 2015; 11(7):1161-78. PubMed ID: 26043024
[TBL] [Abstract][Full Text] [Related]
24. Pim2 complements Flt3 wild-type receptor in hematopoietic progenitor cell transformation.
Agrawal S; Koschmieder S; Bäumer N; Reddy NG; Berdel WE; Müller-Tidow C; Serve H
Leukemia; 2008 Jan; 22(1):78-86. PubMed ID: 17943165
[TBL] [Abstract][Full Text] [Related]
25. Cotreatment with 17-allylamino-demethoxygeldanamycin and FLT-3 kinase inhibitor PKC412 is highly effective against human acute myelogenous leukemia cells with mutant FLT-3.
George P; Bali P; Cohen P; Tao J; Guo F; Sigua C; Vishvanath A; Fiskus W; Scuto A; Annavarapu S; Moscinski L; Bhalla K
Cancer Res; 2004 May; 64(10):3645-52. PubMed ID: 15150124
[TBL] [Abstract][Full Text] [Related]
26. Transcription factor IKZF1 is degraded during the apoptosis of multiple myeloma cells induced by kinase inhibition.
Liu Y; He X; Sui Y; Yu R; Xu G
FEBS Lett; 2015 Aug; 589(17):2233-40. PubMed ID: 26183205
[TBL] [Abstract][Full Text] [Related]
27. Elevated PIM2 gene expression is associated with poor survival of patients with acute myeloid leukemia.
Kapelko-Slowik K; Owczarek TB; Grzymajlo K; Urbaniak-Kujda D; Jazwiec B; Slowik M; Kuliczkowski K; Ugorski M
Leuk Lymphoma; 2016 Sep; 57(9):2140-9. PubMed ID: 26764044
[TBL] [Abstract][Full Text] [Related]
28. PIM2 kinase is induced by cisplatin in ovarian cancer cells and limits drug efficacy.
Musiani D; Hammond DE; Cirillo L; Erriquez J; Olivero M; Clague MJ; Di Renzo MF
J Proteome Res; 2014 Nov; 13(11):4970-82. PubMed ID: 25099161
[TBL] [Abstract][Full Text] [Related]
29. The serine/threonine kinase Pim-2 is a novel anti-apoptotic mediator in myeloma cells.
Asano J; Nakano A; Oda A; Amou H; Hiasa M; Takeuchi K; Miki H; Nakamura S; Harada T; Fujii S; Kagawa K; Endo I; Yata K; Sakai A; Ozaki S; Matsumoto T; Abe M
Leukemia; 2011 Jul; 25(7):1182-8. PubMed ID: 21475253
[TBL] [Abstract][Full Text] [Related]
30. Knockdown of DEPTOR inhibits cell proliferation and increases chemosensitivity to melphalan in human multiple myeloma RPMI-8226 cells via inhibiting PI3K/AKT activity.
Zhang HR; Chen JM; Zeng ZY; Que WZ
J Int Med Res; 2013 Jun; 41(3):584-95. PubMed ID: 23613505
[TBL] [Abstract][Full Text] [Related]
31. Fructose-1, 6-bisphosphatase 1 interacts with NF-κB p65 to regulate breast tumorigenesis via PIM2 induced phosphorylation.
Lu C; Ren C; Yang T; Sun Y; Qiao P; Han X; Yu Z
Theranostics; 2020; 10(19):8606-8618. PubMed ID: 32754266
[No Abstract] [Full Text] [Related]
32. PIM kinases: an overview in tumors and recent advances in pancreatic cancer.
Xu J; Zhang T; Wang T; You L; Zhao Y
Future Oncol; 2014 Apr; 10(5):865-76. PubMed ID: 24799066
[TBL] [Abstract][Full Text] [Related]
33. Noxa up-regulation and Mcl-1 cleavage are associated to apoptosis induction by bortezomib in multiple myeloma.
Gomez-Bougie P; Wuillème-Toumi S; Ménoret E; Trichet V; Robillard N; Philippe M; Bataille R; Amiot M
Cancer Res; 2007 Jun; 67(11):5418-24. PubMed ID: 17545623
[TBL] [Abstract][Full Text] [Related]
34. N- and C-terminal degradation of ecdysteroid receptor isoforms, when transiently expressed in mammalian CHO cells, is regulated by the proteasome and cysteine and threonine proteases.
Schauer S; Burster T; Spindler-Barth M
Insect Mol Biol; 2012 Jun; 21(3):383-94. PubMed ID: 22568680
[TBL] [Abstract][Full Text] [Related]
35. Expression, adverse prognostic significance and therapeutic small molecule inhibition of Polo-like kinase 1 in multiple myeloma.
Evans RP; Dueck G; Sidhu R; Ghosh S; Toman I; Loree J; Bahlis N; Klimowicz AC; Fung J; Jung M; Lai R; Pilarski LM; Belch AR; Reiman T
Leuk Res; 2011 Dec; 35(12):1637-43. PubMed ID: 21816470
[TBL] [Abstract][Full Text] [Related]
36. Engineered Fully Human Single-Chain Monoclonal Antibodies to PIM2 Kinase.
Kaewchim K; Glab-Ampai K; Mahasongkram K; Chulanetra M; Seesuay W; Chaicumpa W; Sookrung N
Molecules; 2021 Oct; 26(21):. PubMed ID: 34770845
[TBL] [Abstract][Full Text] [Related]
37. Activation of mammalian target of rapamycin in transformed B lymphocytes is nutrient dependent but independent of Akt, mitogen-activated protein kinase/extracellular signal-regulated kinase kinase, insulin growth factor-I, and serum.
Wlodarski P; Kasprzycka M; Liu X; Marzec M; Robertson ES; Slupianek A; Wasik MA
Cancer Res; 2005 Sep; 65(17):7800-8. PubMed ID: 16140948
[TBL] [Abstract][Full Text] [Related]
38. Knockdown of c-Met enhances sensitivity to bortezomib in human multiple myeloma U266 cells via inhibiting Akt/mTOR activity.
Que W; Chen J; Chuang M; Jiang D
APMIS; 2012 Mar; 120(3):195-203. PubMed ID: 22339676
[TBL] [Abstract][Full Text] [Related]
39. FV-162 is a novel, orally bioavailable, irreversible proteasome inhibitor with improved pharmacokinetics displaying preclinical efficacy with continuous daily dosing.
Wang Z; Dove P; Wang X; Shamas-Din A; Li Z; Nachman A; Oh YJ; Hurren R; Ruschak A; Climie S; Press B; Griffin C; Undzys E; Aman A; Al-awar R; Kay LE; O'Neill D; Trudel S; Slassi M; Schimmer AD
Cell Death Dis; 2015 Jul; 6(7):e1815. PubMed ID: 26158521
[TBL] [Abstract][Full Text] [Related]
40. Pim-3, a proto-oncogene with serine/threonine kinase activity, is aberrantly expressed in human pancreatic cancer and phosphorylates bad to block bad-mediated apoptosis in human pancreatic cancer cell lines.
Li YY; Popivanova BK; Nagai Y; Ishikura H; Fujii C; Mukaida N
Cancer Res; 2006 Jul; 66(13):6741-7. PubMed ID: 16818649
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
